Preliminary results from this trial indicate that treatment with PRX-08066 resulted in a statistically significant reduction in systolic pulmonary blood pressure during exercise hypoxia.
The trial explored the effects of PRX-08066 on pulmonary blood pressure during hypoxia challenges in the athletic adults who are conditioned to low oxygen pressure environments, such as high altitudes. Because of their conditioning at high altitudes, these volunteers are more able to tolerate increases in pulmonary pressures when challenged with inhalation of hypoxic gas mixtures.
“We are very pleased with the preliminary results from this phase Ib trial of PRX-08066,” said Dr Michael Kauffman, president and CEO of Predix. “We believe PRX-08066 has the potential to meet a significant unmet need among patients suffering from the debilitating effects of pulmonary hypertension (PH).”
Predix recently announced a definitive agreement to merge with Epix Pharmaceuticals.